未找到相关数据
Phase 1b/2, open-label dose-escalation and -expansion study evaluating trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with HER2+and HER2-low gastric cancer (GC): DESTINY-Gastric03 (DG-03)
被引：0
作者：
Janjigian, Yelena Y.
Raoufmoghaddam, Saeed
Sztachelska, Magdalena
Winter, Megan
Das, Satya
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY USA
[2] AstraZeneca, Late Stage Dev, Oncol R&D, Cambridge, England
[3] AstraZeneca, Late Stage Dev, Oncol R&D, Warsaw, Poland
[4] AstraZeneca, Biostat, Oncol R&D, Cambridge, England
[5] AstraZeneca, Late Stage Dev, Oncol R&D, Gaithersburg, MD USA
关键词：
613-213-2711-3371;
283-2511;
298-145-222-184-1022-9124;
261-566-148;
261-492-2769;
298-145-222-184-1022-9126;
298-145-222-184-1022-9122;
6;
4;
3;
2;
1704;
54;
3337;
291;
242;
92;
8;
1;
D O I：
10.1200/JCO.2024.42.3_suppl.TPS424
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：TPS424 / TPS424
页数：1
相关论文